CISPLATIN "EBEWE" 10mg Price

Overview

Welcome to Dwaey, specifically on CISPLATIN "EBEWE" 10mg page.
This medicine contains an important and useful components, as it consists of
Cisplatinis available in the market in concentration

Name

Cisplatin

Precaution

Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity. Lactation: excreted in breast milk; do not nurse

Indication

Lymphomas, Sarcomas, Carcinomas, Small cell lung cancer, Ovarian cancer, Germ cell tumors, Metastatic Testicular Tumors, Metastatic Ovarian Tumors, Advanced Bladder Cancer

Contra indication

Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation.

Side Effect

>10% Nausea (76-100%),Vomiting (76-100%),Nephrotoxicity (28-36%),Ototoxicity, especially in children (31%),Myelosuppression (25-30%),Anaphylaxis (1-20%),Alopecia Frequency Not Defined Cerebral herniation,Encephalopathy,Leukoencephalopathy and reversible posterior leukoencephalopathy syndrome,Seizure,Peripheral neuropathy (dose and duration dependent),Diarrhea,Electrolyte changes,Hyperuricemia,Hepatotoxicity,Local tissue irritation Potentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities.

Pregnancy Category ID

4

Mode of Action

Cisplatin modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs e.g. fluorouracil. It has a narrow therapeutic margin and is highly toxic.

Interaction

Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ?100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression. Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration